Chronic Myeloid Leukemia Clinical Trials

A listing of Chronic Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 152 clinical trials
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment (DASTOP2)

This study will enroll CML patients who have failed a first TKI stopping attempt. After failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment for another 2

  • 30 views
  • 04 Mar, 2022
  • 15 locations
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies

Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML

ponatinib
  • 32 views
  • 18 May, 2022
  • 52 locations
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase

dasatinib
asciminib
imatinib
basophils
nilotinib
  • 0 views
  • 11 Aug, 2022
  • 37 locations
KRT-232 and TKI Study in Chronic Myeloid Leukemia

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or

nilotinib
chronic phase chronic myeloid leukemia
leukemia
dasatinib
tyrosine
  • 12 views
  • 05 Apr, 2022
  • 24 locations
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs

  • 18 views
  • 25 Mar, 2022
  • 15 locations
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase

The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected TKI for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The

  • 1 views
  • 18 Sep, 2022
  • 128 locations
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) (CARTIER)

total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing

breast cancer
lymphoma
primary cancer
early detection
cancer
  • 7 views
  • 17 Jun, 2022
  • 1 location
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

alopecia
blast crisis
chronic myeloid leukemia
RET
ponatinib
  • 34 views
  • 16 Sep, 2022
  • 11 locations
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

nilotinib
leukemia
dasatinib
imatinib
lipase
  • 0 views
  • 09 Jul, 2022
  • 1 location
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Myeloid Leukemia in chronic phase (CML-CP)

calcium
chronic myeloid leukemia
potassium
neutrophil count
asciminib
  • 62 views
  • 12 Jul, 2022
  • 3 locations